What is Shape Therapeutics?
Headquartered in Seattle, Washington, Shape Therapeutics is a pioneering biotechnology firm dedicated to the development of next-generation RNA technologies. The company's comprehensive platform includes RNAskip, RNAfix, and RNAswap, which are designed to address the root causes of genetic diseases. By integrating its proprietary AAVid tissue-specific delivery technology with the SquareBio manufacturing solution, Shape Therapeutics is effectively industrializing the production of gene therapies.
At the heart of the company's innovation is its AI engine, which leverages vast datasets to optimize therapeutic design and accelerate the path to clinical application. This data-centric approach positions Shape Therapeutics at the forefront of the precision medicine market, enabling the company to pursue its mission of delivering lifelong cures for patients with complex genetic conditions.
How much funding has Shape Therapeutics raised?
Shape Therapeutics has raised a total of $147.5M across 2 funding rounds:
Series A
$35.5M
Series B
$112M
Series A (2019): $35.5M with participation from New Enterprise Associates and CureDuchenne Ventures
Series B (2021): $112M led by Decheng Capital, Mission BioCapital, Breton Capital, New Enterprise Associates, and Willett Advisors
Key Investors in Shape Therapeutics
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a venture capital firm focused on helping entrepreneurs build businesses.
Decheng Capital
Decheng Capital is a global investment firm specializing in providing capital and strategic support to early-stage life science and growth-stage healthcare companies.
Willett Advisors
Willett Advisors manages the philanthropic assets of Michael R. Bloomberg, focusing on long-term capital appreciation through a diversified portfolio including private equity and direct investments.
What's next for Shape Therapeutics?
With the support of its latest capital injection, Shape Therapeutics is well-positioned to scale its manufacturing capabilities and advance its pipeline toward clinical trials. The strategic focus will likely remain on the refinement of its AI-driven discovery engine and the expansion of its AAVid delivery platform to address a broader range of therapeutic targets. As the company moves into this next phase of development, the emphasis will shift toward operational excellence and the validation of its gene therapy candidates in human subjects. The firm's ability to maintain strong partnerships with its investor base will be critical as it navigates the complexities of the regulatory landscape and seeks to establish a dominant market presence in the global gene therapy sector.
See full Shape Therapeutics company page
